The September 2026 DAYBREAK readout is the dominant near-term catalyst, positive non-inferiority data for Zenkuda or KSI-501 vs aflibercept could unlock a multi-billion dollar anti-VEGF market opportunity. Monitor for any pre-read or data leaks ahead of the expected topline release. Cash runway into 2027 provides a buffer, but a negative readout would likely force a dilutive financing or strategic alternative.
Drugs in focus
KOD drug pipeline →KSI-101
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
- Next catalyst
- None dated
What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 14 $41.35entry
- T+1 · 3mo ago −0.89%α −0.42% · $40.98
- T+5 · 3mo ago −7.30%α −5.94% · $38.33
- T+20 · 2mo ago −19.85%α −17.86% · $33.14
- T+60 · 8d ago +159.01%α +162.05% · $107.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spending up 31% to $56.1M as clinical activities ramp. The stock's primary catalyst is the upcoming September 2026 DAYBREAK Phase 3 topline data for Zenkuda and KSI-501 in wet AMD, followed by December 2026 PEAK data for KSI-101 in MESI. Cash of $125.9M is expected to fund operations into 2027, but the widening loss and lack of revenue make this a binary event-driven pre-commercial biotech story.
Key Financial Metrics
Key Facts
- Net loss Q2 2026: $65.6M ($1.05/share) vs $54.3M ($1.03/share) in Q2 2025
- Cash and cash equivalents: $125.9M as of June 30, 2026
- R&D expenses: $56.1M in Q2 2026, up from $42.8M in Q2 2025
- DAYBREAK Phase 3 topline data (Zenkuda & KSI-501) expected September 2026
- PEAK Phase 3 Pivotal Analysis 1 topline data (KSI-101) expected December 2026
- ALTO Phase 3 study (KSI-501 in DME) now enrolling patients
- BLA preparation activities for Zenkuda ongoing
- No revenue reported; company is pre-commercial
Financial Impact
Net loss widened by $11.3M YoY to $65.6M; cash burn rate ~$42M/quarter based on $125.9M cash vs $209.9M at year-end 2025
Risk Factors
- Phase 3 DAYBREAK study fails to meet non-inferiority primary endpoint
- Cash runway only into 2027; potential need for dilutive financing if development timelines slip
- Regulatory or manufacturing delays for Zenkuda BLA submission
- Competitive landscape: existing anti-VEGF therapies (aflibercept, faricimab) with established market positions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851311 |
Track record
13 reports on KOD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $111.19 −5.97% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $111.19 −1.54% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $111.19 +0.00% settles Dec 14
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $111.19 +3.82% settles Dec 8
- Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $111.19 −26.76% settles Nov 18
- Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
- Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $111.19 +23.65% ▼ −0.36% −0.32% vs SPY
- Aug 13, 202613w ago 8-K Neutral 4/10 No price data
- Aug 13, 202613w ago Press Release Neutral 6/10 Viewing Entry $41.35 to $33.14 Now $111.19 +168.90% ▼ −19.85% −17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers